(Q46735742)

24 December 2017

title

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma (English)

1 reference

24 December 2017

1 reference

5

Ruben Niesvizky

1 reference

24 December 2017

author name string

Morton Coleman

1

1 reference

24 December 2017

Peter Martin

2

1 reference

24 December 2017

Jia Ruan

3

1 reference

24 December 2017

Richard Furman

4

1 reference

24 December 2017

Rebecca Elstrom

6

1 reference

24 December 2017

Patricia George

7

1 reference

24 December 2017

John Leonard

8

1 reference

24 December 2017

Thomas Kaufmann

9

1 reference

24 December 2017

publication date

1 March 2008

1 reference

24 December 2017

published in

Leukemia & Lymphoma

1 reference

24 December 2017

volume

49

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

447-450

1 reference

24 December 2017

Biology and management of mantle cell lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701837330

10.1080/10428190701837330

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017